series-a
Stage
2018
Founded
1
Investors
About
AbolerIS Pharma develops potentially best-in-class and first-in-class, curative-intent therapies designed to restore immune tolerance by inducing an immune system reset. The company is advancing a novel class of antibodies that target CD45RC, a key marker on pathogenic Effector T and B cells, to restore immune tolerance by selectively depleting the Effector cells while preserving Regulatory cells and overall immune memory.
Explore ABOLERIS PHARMA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.